Pathogenic bacteria

Global Health Leaders Unite to Confront Urgent Public Health Crisis of Antimicrobial Resistance

Retrieved on: 
Tuesday, May 7, 2024
Public Policy, Government, Other Communications, General Health, Health, Other Policy Issues, Infectious Diseases, Communications, Public, Cancer, Antimicrobial resistance, Social isolation, Pathogenic bacteria, Risk, Malaria, CDC, Animal, AMR, Death, Biotechnology Innovation Organization, Parent, Research, BIO, Plant, Friends, Environment, Human, Partnership, Disease, Family, JD, Patient, Caregiver, Face, Diary, Child, HIV, Infection, Associate, TB, COVID-19, Diplomatic rank, Pharmaceutical industry

Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.

Key Points: 
  • Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.
  • "Antimicrobial resistance is an urgent global public health threat that poses risks to modern medicine, the health of humans, animals, plants, the environment, and the global economy.
  • These stories are poised to transform the AMR crisis from a distant concept to a relatable and urgent reality.
  • Putting a human face on this global emergency is critical to motivating action that can change the course of this escalating health crisis.

New Tool Reveals Gene Behavior in Bacteria

Retrieved on: 
Wednesday, January 24, 2024
Death, ECG, DNA replication, Alfred P. Sloan Foundation, TRIPS Agreement, Heart, DNA, Ralph, Champaign–Urbana metropolitan area, Publishing, Gene, University, Medicine, Genetics, Environment, Tick, In situ hybridization, Bacteria, NYU, Human, Cell cycle, Disease, NYU Langone Health, Protein, Nature, Doctor of Philosophy, Genome, National Institutes of Health, Messenger, Gene expression, Bangladesh Technical Education Board, Pathogenic bacteria, TRIP, Cell, Vaccine

This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.

Key Points: 
  • This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.
  • According to the study authors, organisms from bacteria to humans grow as their cells multiply by dividing, with each cell becoming two.
  • Specifically, the research team found that when DNA polymerase arrives at any specific gene, it disrupts the transcription in a way that reveals the state of that gene's regulatory status.
  • Ultimately, they believe that improvements in technology will enable them to dive ever deeper into gene behaviors in different bacterial species.

Veterinary Infectious Disease Diagnostics Global Market Report 2023: A $2.74 Billion Market by 2027 - Rising Zoonotic Disease Incidences Drive Market Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 22, 2023
Veterinary, Health, Human, Pathogenic bacteria, Dog, Infection, University, Parasitism, Mutation, Incidence, Death, Gold, Zoonosis, Animal, Pet, Viral, Rabies, Growth, WHO, RT, Pithing, World Health Organization, Vaccine

The veterinary infectious disease diagnostics market research report provides veterinary infectious disease diagnostics market statistics, including veterinary infectious disease diagnostics industry global market size, regional shares, competitors with a veterinary infectious disease diagnostics market share, detailed veterinary infectious disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary infectious disease diagnostics industry.

Key Points: 
  • The veterinary infectious disease diagnostics market research report provides veterinary infectious disease diagnostics market statistics, including veterinary infectious disease diagnostics industry global market size, regional shares, competitors with a veterinary infectious disease diagnostics market share, detailed veterinary infectious disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary infectious disease diagnostics industry.
  • Technological advancements have emerged as the key trend gaining popularity in the veterinary infectious disease diagnostics market.
  • Major companies operating in the veterinary infectious disease diagnostics market are introducing new technological innovations to sustain their position in the market.
  • Therefore, the increasing incidence of transboundary and zoonotic diseases is driving the growth of the veterinary infectious disease diagnostics market.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023
Patent, Intellectual property, Inhalation, Australian patent law, Pathogenic bacteria, Conditioned place preference, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Coronavirus, COVID-19, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Biology, Ross River virus, Viral, Infection, Bacteria, Family, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Removing antimicrobial resistance from the WHO’s ‘pandemic treaty’ will leave humanity extremely vulnerable to future pandemics

Retrieved on: 
Sunday, June 4, 2023
Plague, Health policy, Pathogenic bacteria, Antimicrobial stewardship, Methicillin-resistant Staphylococcus aureus, Coronavirus, Infection, Policy, COVID-19, MRSA, INB, Global Leaders Group on Antimicrobial Resistance, World Health Assembly, Research, Goal, AMR, Fungus, Language, Hygiene, Genetically modified bacteria, Death, Pandemic, Antimalarial medication, Journal, Publishing, Animal, Antimicrobial, Patient, Risk, Cholera, Sanitation, Water, Intergovernmental, Parasitism, Tuberculosis, Bacteria, World, WHO, Environment, Virus, Pneumonia, World Health Organization, Vaccine, Medicine, Ethics, Northwestern University

The text was made available online via Health Policy Watch and it quickly became apparent that all mentions of addressing antimicrobial resistance in the Pandemic Instrument were at risk of removal.

Key Points: 
  • The text was made available online via Health Policy Watch and it quickly became apparent that all mentions of addressing antimicrobial resistance in the Pandemic Instrument were at risk of removal.
  • Just three years after the onset of a global pandemic, it is understandable why Member States negotiating the Pandemic Instrument have focused on preventing pandemics that resemble COVID-19.
  • But not all pandemics in the past have been caused by viruses and not all pandemics in the future will be caused by viruses.

Antimicrobial resistance

    • Antimicrobial resistance (AMR) is the process by which infections caused by microbes become resistant to the medicines developed to treat them.
    • AMR is fueling the rise of drug-resistant infections, including drug-resistant tuberculosis, drug-resistant pneumonia and drug-resistant Staph infections such as methicillin-resistant Staphylococcus aureus (MRSA).
    • That’s why the potential removal of measures that would help mitigate AMR and better safeguard antimicrobial effectiveness is so concerning.


    The exclusion of these measures would hinder efforts to protect people from future pandemics, and appears to be part of a broader shift to water-down the language in the Pandemic Instrument, making it easier for countries to opt-out of taking recommended actions to prevent future pandemics.

Making the ‘pandemic treaty’ more robust

    • They outlined that including bacterial pathogens in the definition of “pandemics” was critical.
    • They also identified specific provisions that should be tweaked to track and address both viral and bacterial threats.
    • These included AMR and recommended harmonizing national AMR stewardship rules.

Next steps

    • The Pandemic Instrument is the best option to mitigate AMR and safeguard lifesaving antimicrobials to treat secondary infections in pandemics.
    • AMR exceeds the capacity of any single country or sector to solve.
    • If governments are serious about pandemic preparedness, they must support bold measures to conserve the effectiveness of antimicrobials within the Pandemic Instrument.

Global Sepsis Diagnostic Market Report to 2030 - Featuring BioMerieux, Thermo Fisher Scientific, Abbott Laboratories and Bruker Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022
Medical Devices, Health, Blood pressure, Prevalence, Pathogenic bacteria, Infection, Microbiology, CAGR, Inflammation, Growth, Septic shock, Immune system, Vaccine, Oil, Sepsis

When this response goes awry, it causes inflammation, which leads to sepsis.

Key Points: 
  • When this response goes awry, it causes inflammation, which leads to sepsis.
  • In addition, increase in burden of sepsis and rise in global geriatric population propel the market growth.
  • Depending on product, the blood culture media segment held the largest share in the global market in 2020.
  • By pathogen, the bacterial sepsis segment held the largest market share in 2020, and is expected to remain dominant during the forecast period.

The Global Antibiotics Market Will Grow to USD 59,253.24 Million by 2028, at a CAGR of 3.76% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 15, 2022
Health, General Health, Food and Drug Administration, Bacteria, D, AOM, Economy, Antibiotic sensitivity testing, Development, ASM, Society, Enterobacteriaceae, World, Ill, Geography, Infection, WHO, Bronchitis, Antibiotic, COVID-19, Macrolide, Upper respiratory tract infection, CAGR, Pathogenic bacteria, Pneumonia, Hospital, World Health Organization, Aminoglycoside, Organization, NCBI, Campylobacteriosis, Sulfonamide, 33, Meningitis, Food, Prevalence, Azerbaijan and Organization for Economic Co-operation, Sinusitis, Growth, Death, Diarrhea, Protein, RNA, UNICEF, Genetically modified bacteria, DNA, Poultry, Pharyngitis, Vaccine

The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.

Key Points: 
  • The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.
  • The growing prevalence of bacterial infection is one of the major factors increasing the demand for antibiotics globally.
  • Such potential increase in prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period.
  • Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others.

Global $87.1 Mn Orthopedic Implant Antibacterial Coatings Surface Treatment Market to 2028: Technological Advancements in Antibacterial Coatings - ResearchAndMarkets.com

Retrieved on: 
Monday, February 21, 2022
Biotechnology, Health, Surgery, Infection, National Center for Health Statistics, CDC, Federal Statistical Office of Germany, Canadian International Council, PSM, Prevalence, Center, Bank Melli Iran, Joint, COVID-19, Nail, National Health and Nutrition Examination Survey, Centers for Disease Control and Prevention, Pathogenic bacteria, AAOS, National Center for Biotechnology Information, Bacteria, International Trade Administration, BMI, World Health Organization, Patient, AME Publishing Company, American Academy of Orthopaedic Surgeons, LCC, CAGR, Solution, Incidence, ASM, DOT, Hospital, Pharmaceutical industry, Medical device, Antibiotics

The "Orthopedic Implant Antibacterial Coatings Surface Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orthopedic Implant Antibacterial Coatings Surface Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The increasing prevalence of implant-associated infections is one of the prominent factors driving the orthopedic implant antibacterial coatings surface treatment market.
  • Based on type, the global orthopedic implant antibacterial coatings surface treatment market is segmented into passive surface finishing/modifications (PSM), active surface finishing/modifications (ASM), and peri-operative antibacterial local carriers or coatings (LCC).
  • Based on material type, the orthopedic implant antibacterial coatings surface treatment market is segmented into metallic coatings and non-metallic coatings.

Zynex Files Utility Patent for Sepsis Monitor

Retrieved on: 
Wednesday, January 5, 2022
Time, Caregiver, Degenerative disease, Septic shock, COVID-19, Liver, Exchange, Company, Sepsis, Blood pressure, Patient, Kidney, Risk, U.S. Securities and Exchange Commission, Annual report, Security (finance), Tissue, CEO, NASDAQ, Hospital, Health, Infection, Private Securities Litigation Reform Act, Method, Sale, Brain, Pain management, Heart, Pathogenic bacteria, Rehabilitation, Form 8-K, Death, Medical imaging, Pharmaceutical industry

(NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today reported it has filed for a utility patent for its multi-parameter, noninvasive sepsis monitor.

Key Points: 
  • (NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today reported it has filed for a utility patent for its multi-parameter, noninvasive sepsis monitor.
  • This submission follows a provisional patent application on sepsis monitoring the Company filed in January 2021.
  • In the U.S. alone, over 1.7 million adults will develop sepsis annually, resulting in approximately 300,000 deaths," said Thomas Sandgaard, CEO of Zynex.
  • Bacterial infections are the most common cause of sepsis, but sepsis can also be caused by fungal, parasitic, or viral infections.

DGAP-News: AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

Retrieved on: 
Friday, October 22, 2021
MSD, Infection, Nitric oxide, Diabetes, Biotechnology, Cell wall, HCMV, Diagnosis, Quality of life, Gram, Absence, CMV, Gram-positive bacteria, Immune system, Human, Virus, Patient, Gram-negative bacteria, Sepsis, Hepatitis B virus, Biofilm, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Osmotic pressure, HSV, Multiple organ dysfunction syndrome, Letermovir, Amputation, Company, Disease, Transplant, Veterinary medicine, CEO, Inflammation, Chemistry (relationship), German Future Prize, Bone marrow, WHO, Mortality, Hospital, Pathogenic bacteria, Prevalence, Incidence, Drug of last resort, HBV, Pharmaceutical industry, Vaccine, Fine chemical, Antibiotics, Artilysin(R) - a new class of molecules with a novel resistance-breaking mode of action and the potential to replace common antibiotics, Chronic Wounds and Diabetic Foot Infections, Lysando AG, AiCuris Anti-infective Cures AG, ARTILYSIN(R) - A NEW CLASS OF MOLECULES WITH A NOVEL RESISTANCE-BREAKING MODE OF ACTION AND THE POTENTIAL TO REPLACE COMMON ANTIBIOTICS, CHRONIC WOUNDS AND DIABETIC FOOT INFECTIONS, LYSANDO AG, AICURIS ANTI-INFECTIVE CURES AG

As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.

Key Points: 
  • As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.
  • Of note, in contrast to a systemic treatment, a topical formulation would also be beneficial in terms of antibiotic stewardship considerations.
  • In addition, the specificity of Artilysin(R)s ensures the preservation of the natural healthy human microbiome and impede recolonization of pathogens.
  • Bacterial infection is the likeliest single cause of delayed healing of chronic open wounds by secondary intention such as diabetic foot infections.